High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 4/21/2016 |
| Start Date: | September 2006 |
| End Date: | December 2014 |
Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy
High dose rate (HDR) brachytherapy is a form of radiation treatment using temporary
radioactive seeds. This is done by placing very tiny catheters or tubes into the prostate
and then inserting temporary radioactive seeds, called Iridium 192, through these catheters.
HDR brachytherapy gives precise radiation to the prostate with less radiation given to the
normal tissues near the prostate. For patients who have been treated with external beam
radiation to the prostate before, HDR brachytherapy can give radiation again to the prostate
without exposing the normal tissues around the prostate to significantly more radiation.
This may be safer than giving external beam radiation again. The purpose of this study is to
test the safety of high dose rate temporary brachytherapy (HDR) for prostate cancer that has
come back after external beam radiation. We want to find out what effects, good and/or bad,
the treatment has on you and your recurrent prostate cancer.
radioactive seeds. This is done by placing very tiny catheters or tubes into the prostate
and then inserting temporary radioactive seeds, called Iridium 192, through these catheters.
HDR brachytherapy gives precise radiation to the prostate with less radiation given to the
normal tissues near the prostate. For patients who have been treated with external beam
radiation to the prostate before, HDR brachytherapy can give radiation again to the prostate
without exposing the normal tissues around the prostate to significantly more radiation.
This may be safer than giving external beam radiation again. The purpose of this study is to
test the safety of high dose rate temporary brachytherapy (HDR) for prostate cancer that has
come back after external beam radiation. We want to find out what effects, good and/or bad,
the treatment has on you and your recurrent prostate cancer.
Inclusion Criteria:
- KPS > than or equal to 80
- Able to give informed consent
- Able to complete toxicity scales and questionnaires
- Histologically MSKCC confirmed diagnosis of recurrent prostate cancer.
- Documented history of definitive radiotherapy to the prostate gland
- IPSS of < than or equal to 15 at the time of evaluation
- PSA < than or equal to 15 ng/ml
- Organ confined disease
Exclusion Criteria:
- Unable to tolerate general anesthesia
- Abnormal complete blood count. Any of the following:
- Platelet count less than 75,000/ml
- Hb level less than 10 gm/dl
- WBC less than 3.5/ml
- Abnormal coagulation profile:
- INR > 2.5
- Abnormal Liver function tests (>1.5 x normal value)
- Abnormal renal function tests (creatinine > 1.5)
- Evidence of metastatic disease (bone scan, radiographs, MRI findings)
- Prostate volume > 50 cc
- Unable to meet treatment planning criteria
- History of rectal surgery
- External beam radiation dose to the prostate > 86.4 Gy if standard treatment planning
dose constraints were met
- History of inflammatory bowel disease
- Expected survival < 1 year
- Unable to undergo bone scan, CT or MRI evaluation
- Unavailable for regular follow up
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
